Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fareed

Showing results (161-170 of 384) with videos related to

Pageof 39
Sort By:
Haemostasis|January 1, 1988
Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparinsJ Fareed, J M Walenga, D Hoppensteadt, et al.
Thrombosis Research|April 15, 1996
Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping modelJ M Hayes, W Jeske, D Callas, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1991
Comparative studies on various assays for the laboratory evaluation of r-hirudinJ M Walenga, D Hoppensteadt, M Koza, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1991
An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agentJ Fareed, J M Walenga, L Iyer, et al.
Haemostasis|January 1, 1986
Laboratory studies on the intravenous and subcutaneous administration of PK 10169 in manJ Fareed, J M Walenga, D A Hoppensteadt, et al.
Plastic and Reconstructive Surgery|January 15, 1998
Transplantation of lymph node fragments in a rabbit ear lymphedema model: a new method for restoring the lymphatic pathwayK Fu, R Izquierdo, D Vandevender, et al.
Annales Pharmaceutiques Francaises|July 1, 1981
[Low molecular weight oligosaccharides active in plasma against factor Xa. II. New structural elements and antithrombotic activity (author's transl)]J Choay, J C Lormeau, M Petitou, et al.
Thrombosis Research|December 15, 1988
Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activityJ M Walenga, M Petitou, M Samama, et al.
International Angiology : a Journal of the International Union of Angiology|March 16, 2005
Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implicationsM Florian-Kujawski, D Hoppensteadt, J Maddineni, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1986
Functional determination of antithrombin III in clinical samples and therapeutic concentratesJ Fareed, J M Walenga, L G Svendsen, et al.
Pageof 39

Showing results (161-170 of 384) with videos related to

Sort By:
Pageof 39
Haemostasis|January 1, 1988
Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparinsJ Fareed, J M Walenga, D Hoppensteadt, et al.
Thrombosis Research|April 15, 1996
Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping modelJ M Hayes, W Jeske, D Callas, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1991
Comparative studies on various assays for the laboratory evaluation of r-hirudinJ M Walenga, D Hoppensteadt, M Koza, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1991
An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agentJ Fareed, J M Walenga, L Iyer, et al.
Haemostasis|January 1, 1986
Laboratory studies on the intravenous and subcutaneous administration of PK 10169 in manJ Fareed, J M Walenga, D A Hoppensteadt, et al.
Plastic and Reconstructive Surgery|January 15, 1998
Transplantation of lymph node fragments in a rabbit ear lymphedema model: a new method for restoring the lymphatic pathwayK Fu, R Izquierdo, D Vandevender, et al.
Annales Pharmaceutiques Francaises|July 1, 1981
[Low molecular weight oligosaccharides active in plasma against factor Xa. II. New structural elements and antithrombotic activity (author's transl)]J Choay, J C Lormeau, M Petitou, et al.
Thrombosis Research|December 15, 1988
Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activityJ M Walenga, M Petitou, M Samama, et al.
International Angiology : a Journal of the International Union of Angiology|March 16, 2005
Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implicationsM Florian-Kujawski, D Hoppensteadt, J Maddineni, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1986
Functional determination of antithrombin III in clinical samples and therapeutic concentratesJ Fareed, J M Walenga, L G Svendsen, et al.
Pageof 39